PharmaCyte Biotech (OTCQB:PMCB) clinical stage biotechnology company announced a new side of the company by naming Dr. Mark L. Rabe as director of the cannabis development program.
As quoted in the press release:

In his new role, Dr. Rabe will be tasked with leading strategic planning, management and development of PharmaCyte’s Cell-in-a-Box® cannabinoid-based therapy, which is currently in the preclinical research phase. He will also provide operational support to the Chief Executive Officer and executive management team. Dr. Rabe will continue as a member of PharmaCyte’s Medical and Scientific Advisory Board.

PharmaCyte has a license to utilize the Cell-in-a-Box® technology with cannabinoids (constituents of Cannabis) to treat diseases and their related symptoms. PharmaCyte’s “Cannabis Therapy Program” is currently focused on bio-engineering a human cell line that is suitable for Cell-in-a-Box® live-cell encapsulation and capable of producing an enzyme to convert a cannabinoid “prodrug” into its active cancer-killing form. This research seeks to leverage the documented anti-cancer properties of cannabinoid molecules, such as THC (tetrahydrocannabinol) and CBD (cannabidiol).

“We are very pleased to expand Dr. Rabe’s presence at PharmaCyte,” commented PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner. “Dr. Rabe has been superlative in his role as a member of our Medical and Scientific Advisory Board, and now he will be leading our efforts to develop and/or license a marketable Cell-in-a-Box®/cannabinoid therapy. His impressive background in operations, management and educational content development–in addition to his experience as a physician–will also be quite helpful in our planned pivotal clinical trial involving locally-advanced, non-metastatic pancreas cancer.”

Dr. Rabe has worked with PharmaCyte since 2013, when he was appointed as founding member and Chairman of the Medical and Scientific Advisory Board. In this role, he was instrumental in building the Board, designing PharmaCyte’s cannabinoid-based therapy and establishing PharmaCyte’s current Cannabis research program with the University of Northern Colorado. In his new role, Dr. Rabe will assume management of the Cannabis Therapy Program, with the goal of developing a marketable product. With broad experience in business operations, Dr. Rabe will also assist the company in a variety of other areas.

Dr. Rabe’s professional background spans three decades, during which time he has worked as a highly regarded clinical physician, founded and grown several successful healthcare-related businesses, served as Chief Medical Officer of the largest network of physician-owned alternative care centers in the country and served as Medical Director of an e-Learning company that developed educational content for MDs and PhDs at major pharmaceutical companies, such as Eli Lilly, Celgene, Genentech, Amgen and others. Dr. Rabe has also delivered numerous scientific presentations and has served as a Superior Court-approved expert witness in the emerging area of cannabinoid medicine.

Dr. Rabe attended Northwestern University Medical School and he is a diplomate of the American Board of Integrative Holistic Medicine (ABIHM). He received his undergraduate training at Benedictine University, where he earned a summa cum laude degree in biochemistry. Dr. Rabe’s integrative holistic medical practice, Centric Wellness, is in San Diego, California.

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through the encapsulated cells, they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.

In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production.

Click here to read the full press release.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less